

IBB

iShares Nasdaq Biotechnology ETF

Fact Sheet as of 03/31/2018

iShares®
by BLACKROCK®

The iShares Nasdaq Biotechnology ETF seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ.

WHY IBB?

- 1 Exposure to U.S. biotechnology and pharmaceutical companies
- 2 Targeted access to biotechnology and pharmaceutical stocks listed on the NASDAQ
- 3 Use to express a sector view

GROWTH OF 10,000 USD SINCE INCEPTION



The Growth of \$10,000 chart reflects a hypothetical \$10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted.

PERFORMANCE

| | 1 Year | 3 Year | 5 Year | 10 Year | Since Inception |
|--------------|--------|--------|--------|---------|-----------------|
| NAV | 9.41% | -2.16% | 15.06% | 15.71% | 7.18% |
| Market Price | 9.45% | -2.14% | 15.07% | 15.72% | 7.18% |
| Benchmark | 9.81% | -1.88% | 15.38% | 16.01% | 7.52% |

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by visiting www.iShares.com or www.blackrock.com.

Market returns are based upon the midpoint of the bid/ask spread at 4:00 p.m. eastern time (when NAV is normally determined for most ETFs), and do not represent the returns you would receive if you traded shares at other times.

KEY FACTS

| | |
|--------------------|--------------------------------|
| Fund Launch Date | 02/05/2001 |
| Expense Ratio | 0.47% |
| Benchmark | Nasdaq Biotechnology Index (R) |
| 30 Day SEC Yield | 0.12% |
| Number of Holdings | 193 |
| Net Assets | \$9,029,551,261 |
| Ticker | IBB |
| CUSIP | 464287556 |
| Exchange | NASDAQ |

TOP HOLDINGS (%)

| | |
|-----------------------------|-------------|
| CELGENE CORP | 8.29 |
| GILEAD SCIENCES INC | 7.75 |
| BIOGEN INC INC | 7.67 |
| AMGEN INC | 7.51 |
| VERTEX PHARMACEUTICALS INC | 5.57 |
| REGENERON | |
| PHARMACEUTICALS INC | 4.35 |
| ILLUMINA INC | 4.20 |
| ALEXION PHARMACEUTICALS INC | 3.39 |
| MYLAN NV | 3.03 |
| INCYTE CORP | 2.42 |
| | <hr/> 54.18 |

Holdings are subject to change.

TOP SECTORS (%)

| | |
|--------------------------------|--------|
| Biotechnology | 81.50% |
| Pharmaceuticals | 11.37% |
| Life Sciences Tools & Services | 6.57% |
| Health Care Equipment | 0.27% |
| Cash and/or Derivatives | 0.10% |
| Health Care Supplies | 0.09% |
| Health Care Technology | 0.05% |
| Health Care Distributors | 0.05% |

FUND CHARACTERISTICS

| | |
|---------------------------|--------|
| Beta vs. S&P 500 | 0.76 |
| Standard Deviation (3yrs) | 23.70% |
| Price to Earnings | 19.96 |
| Price to Book Ratio | 5.12 |

FEES AND EXPENSES BREAKDOWN

| | |
|----------------------------------|--------------|
| Expense Ratio | 0.47% |
| Management Fee | 0.47% |
| Acquired Fund Fees and Expenses | 0.00% |
| Foreign Taxes and Other Expenses | 0.00% |

GLOSSARY

Beta is a measure of the tendency of securities to move with the market as a whole. A beta of 1 indicates that the security's price will move with the market. A beta less than 1 indicates the security tends to be less volatile than the market, while a beta greater than 1 indicates the security is more volatile than the market.

The price to earnings ratio (P/E) is a fundamental measure used to determine if an investment is valued appropriately. Each holding's P/E is the latest closing price divided by the latest fiscal year's earnings per share. Negative P/E ratios are excluded from this calculation.

The price to book (P/B) value ratio is a fundamental measure used to determine if an investment is valued appropriately. The book value of a company is a measure of how much a company's assets are worth assuming the company's debts are paid off. Each holding's P/B is the latest closing price divided by the latest fiscal year's book value per share. Negative book values are excluded from this calculation.

Want to learn more? www.iShares.com  www.blackrockblog.com  @iShares

Carefully consider the Fund's investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Fund's prospectus, and if available, summary prospectus, which may be obtained by calling 1-800-iShares (1-800-474-2737) or by visiting www.iShares.com or www.blackrock.com. Read the prospectus carefully before investing.

Investing involves risk, including possible loss of principal.

Funds that concentrate investments in a single sector will be more susceptible to factors affecting that sector and more volatile than funds that invest in many different sectors.

On 4/3/14, IBB changed to the total return version of the Nasdaq Biotechnology index from the price return version. Historical index data has been restated to the total return version of the index since index inception on 9/25/03. Historical index data prior to 9/25/03 reflects the price return version.

Diversification may not protect against market risk or loss of principal. Shares of iShares Funds are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

Index returns are for illustrative purposes only. Index performance returns do not reflect any management fees, transaction costs or expenses. Indexes are unmanaged and one cannot invest directly in an index. Past performance does not guarantee future results.

"Acquired Fund Fees and Expenses" reflect the Fund's pro rata share of the indirect fees and expenses incurred by investing in one or more acquired funds, such as mutual funds, business development companies, or other pooled investment vehicles. AFFE are reflected in the prices of the acquired funds and thus included in the total returns of the Fund.

The iShares Funds are distributed by BlackRock Investments, LLC (together with its affiliates, "BlackRock").

"NASDAQ®" is a service/trademark of The Nasdaq OMX Group, Inc. ("NASDAQ OMX") and has been licensed for use by BlackRock. iShares Funds are not sponsored, endorsed, issued, sold or promoted by The Nasdaq OMX Group, Inc. nor does this company make any representation regarding the advisability of investing in iShares Funds. BlackRock is not affiliated with the company listed above. Index data source: NASDAQ OMX.

©2018 BlackRock. All rights reserved. **iSHARES**, **iBONDS** and **BLACKROCK** are registered trademarks of BlackRock Inc, or its subsidiaries. All other marks are the property of their respective owners.

FOR MORE INFORMATION, VISIT WWW.ISHARES.COM OR CALL 1-800 ISHARES (1-800-474-2737)

iS-IBB-F0318

Not FDIC Insured - No Bank Guarantee - May Lose Value

501848

BLACKROCK®